Accordingly, our studies also revealed that the ATP-competitive AKT inhibitor ipatasertib exhibited antiproliferative effects when used in combination with the HER2 inhibitor lapatinib in the HER2+ PIK3CA-mutant breast cancer cell line, while the combination effects with rapamycin were less pronounced. Here, ERBB2 is linked to breast cancer.